bioRxiv · 10.1101/2021.08.13.456164
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model
Abstract
COVID-19 caused by SARS-CoV-2 has been spreading worldwide. To date, several vaccine candidates moved into EUA or CA applications. Although DNA vaccine is on phase III clinical trial, it is a promised technology platform with many advantages. Here, we showed that the pGX9501 DNA vaccine encoded the spike full-length protein-induced strong humoral and cellular immune responses in mice with higher neutralizing antibodies, blocking the hACE2-RBD binding against live virus infection in vitro. Importantly, higher levels of IFN-{gamma} expression in CD8+ and CD4+ T cell and specific cytotoxic lymphocyte (CTL) killings effect were also observed in the pGX9501-immunized group. It provided subsequent protection against virus challenges in the hACE2 transgenic mouse model. Overall, pGX9501 was a promising DNA vaccine candidate against COVID-19, inducing strong humoral immunity and cellular immunity that contributed to the vaccines protective effects.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Jiang, S., Wu, S., Zhao, G., He, Y., Bao, L., Liu, J., Qin, C., Hou, J., Ding, Y., Wu, J., Yan, J., Humeau, L., Patella, A., Weiner, D. B., Broderick, K., Wang, B.. 2021-08-16. Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model. https://doi.org/10.1101/2021.08.13.456164
Cite the original work for its findings. Save a collection to share your selection of sources.